Sign In | Create an Account | Welcome, . My Account | Logout | Subscribe | Submit News | Contact Us | Routes Available | Home RSS
 
 
 

USDA approves shot for cows aimed at E. coli

March 29, 2009
Minot Daily News

MINNEAPOLIS (AP) - A Minnesota company has won federal approval to become the first in the U.S. to market an E. coli vaccine for cattle, a new weapon against a foodborne disease that can cause serious illness and even death in people.

Epitopix LLC was given a conditional license from the U.S. Department of Agriculture to sell its vaccine.

Nayyera Haq, a USDA spokeswoman, called it "an important step toward improving food safety in this country," and a major beef group agreed.

"It really is a major milestone for our industry," Michelle Rossman, director of beef safety research for the National Cattlemen's Beef Association, said Thursday.

Most E. coli bacteria are harmless but one kind, known as O157, sickens an estimated 70,000 people in the U.S. every year, according to the Centers for Disease Control and Prevention. Most recover in a few days, but some get serious complications such as kidney failure. Contaminated beef is a common source and has led to several big recalls in recent years.

James Sandstrom, general manger of Willmar-based Epitopix said the vaccine works by preventing E. coli O157 in cows' intestines from absorbing iron. The company's technology takes the proteins that the bacteria use to absorb iron from the host animal, and injects them back into cattle to generate an immune response against those proteins. The bacteria can't live without the iron.

With fewer bacteria in the intestines, the risk is reduced that they will contaminate the carcass at slaughter.

Sandstrom said the vaccine will enter commercial use this month, but it will be several months before it's widely available. He said some major packers and producers will be the first to use it, but declined to name them, saying they don't want their names associated with E. coli even for research.

It's not clear yet how widely the industry will embrace the vaccine.

"That's the $64 million question," Sandstrom said.

E. coli O157 doesn't make cattle sick, so producers who already face slim profit margins may need incentives. Sandstrom said privately owned Epitopix hasn't set a price for the vaccine yet, but is hoping incentives will come from packers and retailers who would profit from safer beef.

A Canadian company that makes an E. coli vaccine for cattle sells it there for $7 U.S. per cow.

A spokesman for Tyson Foods Inc., one of the nation's largest meat processors, declined to comment. A call to Cargill Meat Solutions wasn't immediately returned.

Rossman said the support is likely to be there. She said the industry has already spent millions of dollars on technologies to fight E. coli in packing houses, and is anxious for strategies that work before slaughter. Her group helped fund research at West Texas A&M University that led the USDA to grant the conditional license. Similar work was also done at Kansas State University.

 
 

 

I am looking for:
in:
News, Blogs & Events Web